A misdiagnosed case of blastic plasmacytoid dendritic cell neoplasm experiencing multiple recurrences who underwent allogeneic stem cell transplantation: a case report

Fateme Salemi1†, Seyed Mohammad Reza Mortazavizadeh2†, Seyyedmohammadsadeq Mirmoeeni3, Amirhossein Azari Jafari3, Farid Kosari4*† and Seyed Sina Naghibi Irvani5*†

Abstract

Background: Blastic plasmacytoid dendritic cell neoplasm represents a rare type of hematologic malignancy that often manifests itself through various skin lesions. It commonly affects the elderly male population. Lymph nodes, peripheral blood, and bone marrow involvement are the typical findings that justify its aggressive nature and dismal prognosis. On histopathological assessment, malignant cells share some similarities with blastic cells from the myeloid lineage that make immunohistochemistry staining mandatory for blastic plasmacytoid dendritic cell neoplasm diagnosis.

Case presentation: A 35-year-old Asian man presented with cervical lymphadenopathy followed by an erythematous lesion on his left upper back. At first, the lesion was misdiagnosed as an infectious disease and made the patient receive two ineffective courses of azithromycin and clarithromycin. Six months later, besides persistent skin manifestations, he felt a cervical mass, which was misdiagnosed as follicular center cell lymphoma. Tumor recurrence following the chemoradiation questioned the diagnosis, and further pathologic assessments confirmed blastic plasmacytoid dendritic cell neoplasm. The second recurrence occurred 3 months after chemotherapy. Eventually, he received a bone marrow transplant after complete remission. However, the patient expired 3 months after transplant owing to the third recurrence and gastrointestinal graft versus host disease complications.

Conclusions: Early clinical suspicion and true pathologic diagnosis play a crucial role in patients' prognosis. Moreover, allogenic bone marrow transplant should be performed with more caution in aggressive forms of blastic plasmacytoid dendritic cell neoplasm because of transplant side effects and high risk of cancer recurrence.

Keywords: Blastic plasmacytoid dendritic cell neoplasm, Immunohistochemistry, Recurrence, Graft versus host disease

Background

Comprising only 0.44% of all hematological malignancies, blastic plasmacytoid dendritic cell neoplasm (BPDCN) manifests as a life-threatening form of hematologic malignancy with an insignificant survival rate (usually less than a year). During its aggressive course, BPDCN often presents with multiple erythematous...
papules and tends to involve peripheral blood, bone marrow, and lymph nodes [1]. In 2008, the World Health Organization changed the tumor’s name from acute myelogenous leukemia to BPDCN and classified it under hematopoietic and lymphoid organ tumors [2, 3]. Since BPDCN demonstrates some overlapping features with other hematologic malignancies, early tumor detection remains challenging. Therefore, a complete history and a physical examination should be accompanied by imaging modalities, flow cytometry, and immunohistochemistry (IHC) of affected tissues to confirm the diagnosis [4–6].

For local and systemic elimination of the neoplastic cells, various therapeutic managements have been approved, including radiotherapy, chemotherapy (similar to acute myeloid leukemia or acute lymphoblastic leukemia chemotherapy drugs), and alloimmune bone marrow stem cell transplantation [7–9]. Here, we present a rare and sophisticated case of a patient with misdiagnosed BPDCN, who experienced multiple recurrences during treatment.

**Case presentation**

In May 2017, a 35-year-old Asian man presented with an infiltrative erythematous plaque and a nodule on his left upper shoulder. He had no fever, chills, or any other symptoms (Fig. 1a, b). At first, he received two courses of azithromycin (Azithrocin) and clarithromycin (Biaxin) (500 mg orally on day 1 followed by 250 mg orally daily on days 2–5 for both antibiotics) to rule out possible infection. During 6 months, besides the lack of response, a palpable cervical mass appeared that was persistent to antimicrobial treatment. Therefore, 2 months later, he was referred to an oncologist for further evaluation. Despite insignificant past medical and family history, complete blood count, and peripheral blood smear, he showed cervical and supraclavicular lymphadenopathy on physical examination.

Cervical lymph node biopsy diagnosis showed diffuse malignant lymphoma, and IHC staining confirmed the tumor subtype as follicular center cell lymphoma (a non-Hodgkin lymphoma). On IHC, malignant cells displayed positive immunoreactivity for CD10, CD20, BCL2, TdT, LCA, and ki67 and negative immunoreactivity for CD3.
| Disease onset | First relapse | Second relapse | Third relapse |
|--------------|--------------|---------------|--------------|
| Skin involvement | Infiltrative erythematous plaque and nodule on left upper shoulder | Ill-defined erythematous nodules on left upper shoulder outside the radiotherapy margin | Two new erythematous nodules on dorsal aspects of left forearm and left leg | Multiple erythematous nodules on upper back, dorsal aspect of right thigh and ventral aspect of left leg |
| Other clinical symptoms | Cervical lymphadenopathy | – | Like the first relapse | Like the first relapse |
| Histopathology | Lymph node biopsy: not mentioned | Skin biopsy: focal intradermal monomorphous infiltrate of medium-sized blast-like cells without any significant mitotic activity or necrosis | Like the first relapse | Like the first relapse |
| Immunohistochemistry | Positive: CD10, CD20, BCL2, TdT, LCA, ki67 | Positive: CD43, CD4, ki67, CD68, CD33, CD56, CD123 | Like the first relapse | Like the first relapse |
| | Negative: CD3, CD4, CD5, CD16, CD30, CD56, CD79a, BCL6, PAX5 | Negative: CD20, CD3, CD30, CD5, CD34, PAX5, CD79a, MP0, Pan CK, Melan A, CD56, TdT, C-kit, CD138, PAX5, CD79a, LCA | – | – |
CD4, CD5, CD16, CD30, CD56, CD79a, BCL6, and PAX-5 (Table 1).

Analysis of bone marrow aspiration and biopsy confirmed the lack of any infiltrative lesion or malignancy. Nevertheless, thoracic and abdominopelvic computed tomography (CT) scans illustrated an enlargement in the left side of the neck and supraclavicular lymph nodes (up to 24 mm in diameter), a nasopharyngeal soft tissue thickening, and a hypodense right liver lobe lesion.

The patient received eight courses of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy regimen and radiotherapy (3600 cGy in 18 fractures) with 6 MeV electron beams. After treatment, skin lesions as well as lymphadenopathy and subcutaneous chest wall infiltrations disappeared. However, small liver lesions did not disappear in the follow-up CT scan. The absence of pathologic hypermetabolic lesions on positron emission tomography–CT (PET-CT) scan was in favor of remission. However, 3 months later, two ill-defined erythematous nodules appeared out of the radiotherapy zone (Fig. 1c), and their histopathology was compatible with BPDCN.

To clarify the controversy in diagnosis, the third pathologist reviewed the first and second specimens and confirmed BPDCN as the true diagnosis. Skin biopsy showed that medium-sized monomorphic blast-like cells focally infiltrated the dermis without any significant signs of mitotic activity or necrosis (Fig. 2a, b). IHC staining of the lesion revealed diffuse positive immunostaining of atypical cells with CD43 and CD4. The tumor also showed scattered ki67 staining (5–10%) and focal dot-like cytoplasmic forms in CD68 immunostaining with weakly positive CD33, CD56, CD123, and LCA. These CD markers were absent: CD20, CD3, CD34, CD5, CD34, PAX5, CD79a, MPO, Pan CK, Melan A, TdT, C-kit, and CD138. Negative LCA and B-cell markers including PAX5, CD20, and CD79a in the IHC study panel made any kind of B-cell lymphoma unlikely (Fig. 2c–e). Therefore, two courses of hyper-CVAD (cyclophosphamide, vincristine, Adriamycin, dexamethasone) started to make the patient courses of hyper-CVAD (cyclophosphamide, vincristine, dexamethasone) started to make the patient

The patient found two new erythematous nodules on the dorsal aspect of his left forearm and left leg, which was confirmed as the second recurrence in biopsy (Fig. 1d). Despite the indication of target therapy with daratumumab and tagraxofusp, the patient received three courses of ifosfamide, carboplatin, and etoposide (ICE) chemotherapy owing to financial issues.

Consequently, following complete remission and normal liver transaminase levels, he underwent SCT from a full-match donor (his sister) as the first eligible case of BPDCN for transplant in Iran. Unfortunately, 2 months later, new skin lesions appeared that made graft versus host disease (GVHD) a probable etiology. However, biopsy confirmed the third recurrence of malignant cells (Fig. 1e, f), and the patient restarted the treatment. A few months later, he experienced severe watery diarrhea and underwent a diagnostic workup for gastrointestinal GVHD. Stool culture ruled out bacterial, fungal, and viral pathogens, and colonoscopy displayed erosion and necrosis of bowel mucosa with shallow ulcers. After the confirmed diagnosis of GVHD, chemotherapy was stopped and the patient received GVHD treatment according to protocols of the American Society of Hematology [10]. Unfortunately, 3 months later, the patient died from GVHD and tumor recurrence complications.

Discussion and conclusions
We have reported a case of BPDCN in a 37-year-old man who presented with a cutaneous lesion at disease onset. BPDCN is an unusual hematologic neoplasm that usually involves patients older than 60 years and has male predominance. Hence, it has a lower incidence among children and adults younger than 50 years old. This tumor initially involves the skin with a nonspecific morphology and distribution ranging from erythematous, purplish papules to bruise-like plaques or patches with size variability (from a few millimeters to several centimeters) and no inclination toward any specific anatomical area [11].

Unusual cutaneous and extracutaneous manifestations have been reported in some cases, including gingival lesions, acute rheumatic fever, pulmonary, central nervous system (CNS), and testicular infiltration [12, 13]. Besides, neoplastic cells metastasize to peripheral blood and bone marrow, lymph nodes, and spleen in 60–90%, 56%, and 34–78% of cases, respectively. Bone marrow is spared at disease onset, though it might be involved as the cancer progresses towards the leukemic phase, which indicates a poor prognosis [14]. Yet, our patient's bone marrow was clear of neoplastic cells and became severely hypocellular as a result of cytotoxic chemotherapy. In BPDCN, peripheral blood may contain medium-sized blasts that have scant cytoplasm, fine nuclear chromatin, and evident nucleoli [15]. On flow cytometry, most of the neoplastic cells that overexpress CD123 may express a positive reactivity for CD4, CD56, CD303, or TCL1. The
neoplastic cells derive from rapidly expanding progenitors of plasmacytoid dendritic cells that originate from the myeloid lineage [16].

Although histopathology showing lymphoblasts or small immunoblasts supports the presence of a neoplastic reaction, it requires IHC staining to verify the diagnosis and distinguish this malignancy from its differential diagnoses [17, 18]. The differential diagnoses of BPDCN include mature T-cell lymphoma, myeloid sarcoma, acute myeloid leukemia, and T-cell lymphoblastic lymphoma [19]. Unlike BPDCN, T-cell biomarkers, including CD3, CD1a, and CD10, are detected in T-cell lymphoblastic lymphoma. Nevertheless, instead of skin involvement, T-cell lymphoblastic lymphoma often presents with a mediastinal mass. As an extramedullary myeloid tumor, myeloid sarcoma consists of myeloblasts or premature myeloid cells [20]. Monoblastic lineage of both BPDCN and myeloid sarcoma express CD56, CD123, and CD4 markers; nevertheless, TdT is exclusively detected in 33% of the BPDCN patients. Despite IHC, clinical manifestations can distinguish myeloid sarcoma from BPDCN. Unlike lymphoid leukemia, myeloid leukemia neoplastic cells, especially the monoid lineage L4 and L5 may share some features in common with blastic plasmacytoid dendritic cells. However, monoblastic leukemia (AML-M5) originates from bone marrow and may metastasize to the skin. On the other hand, BPCDN has a dermal origin and may infiltrate into bone marrow as the disease evolves [19].

Currently, due to insufficient existing data regarding BPDCN and lack of treatment protocols, the patient underwent conventional polychemotherapy (acute lymphoblastic leukemia (ALL)-type, acute myeloid leukemia (AML)-type, and lymphoma-type therapy). In terms of survival outcomes and complete remission rates, ALL treatment is preferred to AML-type treatment. Complete remission rates vary from 55% to 80% in CHOP or CHOP-like regimens; however, recurrence-free survival rarely lasts more than 5 months [7, 21]. In 2018, the FDA approved tagraxofusp or SL401 as the standard treatment for BPDCN since it targets CD123-expressing cells [22]. In vivo and in vitro studies had promising results regarding the efficacy of this drug from phase I and II clinical trials, showing significant improvement in overall survival compared with conventional BPDCN chemotherapy regimens. Tagraxofusp also has some notable side effects, including hypoalbuminemia, elevated transaminases, thrombocytopenia, and capillary leak syndrome [23–25]. Allogeneic or autologous transplant after first complete remission leads to long-term overall survival; nevertheless, from a practical point of view, this may not be feasible owing to advanced age at presentation [26]. Radiotherapy locally eradicates intradermal infiltration, which has shown promising consequences in patients with mere cutaneous manifestations [27].

Despite various therapeutic options, a high recurrence rate has caused a dismal prognosis for BPCDN, which is due to the tumor’s unspecific cutaneous presentation,
aggressive nature, and challenging diagnosis in most patients. Unfortunately, in this case, besides antibiotic resistance, unjustified antimicrobial treatment provoked rapid tumor expansion and multiple recurrences despite high-dose chemotherapeutic and radiotherapy. In addition, allogeneic bone marrow SCT has promising results in patients without recurrence. Nevertheless, its disadvantages outweigh the advantages in recurrent BPDCN, since it imposes likely tumor relapse, GVHD complications, and systemic infections on these patients.

In conclusion, this case highlights the significance of early diagnosis and treatment in BPDCN outcome. Multiple recurrences adversely affect patients’ prognosis; therefore, bone marrow transplant options should be reserved for those without recurrences. In relapsing and aggressive forms, transplant side effects as well as tumor recurrence should be considered to prevent further complications and extra costs.

Abbreviations

BPDCN: Blastic plasmacytoid dendritic cell neoplasm; IHC: Immunohistochecmistry; PET-CT: Positron emission tomography–computed tomography; SCT: Stem cell transplantation; CSF: Cerebrospinal fluid; CBC: Cell blood count; GVHD: Graft versus host disease; CNS: Central nervous system; AML: Acute myeloid leukemia; ALL: Acute lymphoblastic leukemia; CT: Computed tomography.

Acknowledgements

We thank Dr. Maryam Moshtagi for informing us about patient radiotherapy dosage. We also appreciate the patient’s cooperation in sharing useful information about his complicated disease process despite experiencing a hard time fighting this cancer.

Authors’ contributions

SMRM decided to present this patient as a case report and designed the concept of study. FS, FK, AAJ, and SM drafted and revised the manuscript. AAJ, SM, and FS followed up with the patient and acquisition of data. FS, AAJ, and SM wrote the original final manuscript. FK, SSNI, and SMRM reviewed and edited the final version. All authors have read and approved the final manuscript.

References

1. Yang CL, Zhao S, Wang L, Zou LQ. Blastic plasmacytoid dendritic cell neoplasm: a case report. Acta Derm Venereol. 2019;99(4):456–7.
2. Wang T, Liu L, Zhang RY, Guo J. Lymph blastic plasmacytoid dendritic cell neoplasm: a case report and review of literature. Int J Clin Exp Med. 2019;12(1):1127–31.
3. World Health Organization. WHO Classification of tumours of haematopoietic and lymphoid tissues, Fourth Edition. 2008.
4. Mansour Y, Stadler R. Blastic plasmacytoid dendritic cell neoplasm, a rare hematological manifestation of the skin. JDDG. 2019;17:61.
5. Szablewski V, Costes V, Brett C, Dereure O, Yos R, Alame M, et al. Cutaneous presentation preceding acute myeloid leukemia with CD4+/CD56+ expression misdiagnosed as a blastic plasmacytoid dendritic cell neoplasm: a case report. J Cutan Pathol. 2018;45(8):610–4.
6. Owczerzynz-Saczonek A, Sokolowska-Wodylo M, Olzewska B, Malek M, Znajewska-Pander A, Kowalczyk A, et al. Clinicopathologic retrospective analysis of blastoid plasmacytoid dendritic cell neoplasms. Postepy Dermatol Alergol. 2018;35(2):128–38.
7. Bruggen MC, Valencak J, Stranzenbach R, Li N, Stadler R, Jonak C, et al. Clinical diversity and treatment approaches to blastoid plasmacytoid dendritic cell neoplasm: a retrospective multicentre study. Eur J Cancer. 2020. https://doi.org/10.1016/j.ejca.2019.10.062.
8. Dalle S, Beylot-Barry M, Bagot M, Lipser D, Machet L, Joly P, et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol. 2010;162(1):74–9.
9. Economides MP, Konopleva M, Pemmaraju N. Recent developments in the treatment of blastoid plasmacytoid dendritic cell neoplasm. Ther Adv Hematol. 2019. https://doi.org/10.1177/2040620719874733.
10. McDonald GB. How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver. Blood. 2016;127(12):1544–50.
11. Lim MS, Lemmert K, Enjeti A. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a rare entity. BMJ Case Rep. 2016;2016:bcr2015214093. https://doi.org/10.1136/bcr-2015-214093.
12. Xin X, Tian M, Huang LF, Wang GX, Cheng L, Liu ZJ, et al. Cutaneous lesions from a blastoid plasmacytoid dendritic cell neoplasm: a case report and literature review. Int J Clin Exp Med. 2016;9(2):5017–22.
13. Baros Romaro C, Santos Junior CID, Leite LAC, Gomes Alves MIR, Araujo NS, Castro AFL, et al. Blastic plasmacytoid dendritic cell neoplasm with pulmonary involvement and atypical skin lesion. Am J Case Rep. 2017;18:692–5.
14. Lee SE, Park HY, Kwon D, Jeon YK, Kim WY. Blastic plasmacytoid dendritic cell neoplasm with unusual extracutaneous manifestation: two case reports and literature review. Medicine (Baltimore). 2019;98(6):e14344. https://doi.org/10.1097/MD.0000000000014344.
15. Ishibashi N, Maebayashi T, Aizawa T, Sakaguchi M, Abe O, Miura K, et al. Radiation therapy for cutaneous blastoid plasmacytoid dendritic cell neoplasm: a case report and review of the literature. Int J Clin Exp Med. 2015;8(5):8204–9.
16. Hamadeh F, Awadallah A, Meyerson HJ, Beck RC. Flow cytometry identifies a spectrum of maturation in myeloid neoplasms having plasmacytoid cell differentiation. Cytom Part B-Clin Cytom. 2020;98(1):43–51.
17. Pennisi M, Cesana C, Cittone MG, Bandiera L, Scarpatici B, Mancini V, et al. A case of blastoid plasmacytoid dendritic cell neoplasm extensively studied by flow cytometry and immunohistochecmistry. Case Rep Hematol. 2017;2017:1–6.
18. Hwang K, Park CJ, Chi HS, Jang S, Park SJ, Huh JR, et al. Immunohistochecmistry (CD123, CD56 AND CD4) reveals minimal bone marrow
involvement in cases of blastic plasmacytoid dendritic cell neoplasm. Haematologica Hematol J. 2009;94:547–8.
19. Cesarm-Maus G, Lome C, Espinosa KA, Quezada-Fiallos CM, Rivas S, Quezda R. Clinical and pathological features and differential diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN): a series of cases. Blood. 2016;128(22):5183.
20. Trottier AM, Cerquozzi S, Owen CJ. Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects. Blood Lymphat Cancer. 2017;7:85–93.
21. Pemmaraju N. Treatment advances in blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol. 2019;17(4):207–9.
22. Economides MP, McCue D, Lane AA, Pemmaraju N. Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm. Expert Rev Clin Pharmacol. 2019;12(10):941–6.
23. Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385–92.
24. Pemmaraju N, Lane AA, Sweet KL, Stein A, Vasu S, Blum W, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628–37.
25. Alfayez M, Konopleva M, Pemmaraju N. Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). Expert Opin Biol Ther. 2020;20(2):115–23.
26. Qazilbash MH, Ramdial J, Bashir Q, Milton DR, Patel RD, Popat UR, et al. Outcomes of allogeneic hematopoietic stem cell transplantation for BPDCN. Biol Blood Marrow Transplant. 2020;26(3):S106–7.
27. Khan AM, Munir A, Raval M, Mehti S. Blastic plasmacytoid dendritic cell neoplasm in the background of myeloproliferative disorder and chronic lymphocytic leukemia. BMJ Case Rep. 2019. https://doi.org/10.1136/bcr-2019-230332.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.